LipidBrick®IM21.7c: modulating LNPs particle size, charge, stability and biodistribution for optimal mRNA delivery.
DNA and RNA therapeutics are drug products composed of an active genetic component linked to an efficient delivery system, generally Lipid NanoParticles (LNP).
Those treatments include both prophylactic vaccines that prevent an infection by triggering the patient’s immune system and therapeutic vaccines that will be used to cure a patient from a specific disease.
Each therapy will require its own LNP formulation depending on the genetic material and the targeted tissue. To adapt the delivery system to the need, a wide variety of lipids that modulate the encapsulation efficiency and the LNP properties is needed for therapeutic success.
Join this webinar to hear how Polyplus developed LipidBrick® IM21.7c to overcome current limitations of ionizable lipids by enabling a wider in vivo biodistribution and decreasing accumulation in the liver. LipidBrick® IM21.7c aims to to improve LNP formulation to meet the growing demand of the mRNA therapeutic market.
Those treatments include both prophylactic vaccines that prevent an infection by triggering the patient’s immune system and therapeutic vaccines that will be used to cure a patient from a specific disease.
Each therapy will require its own LNP formulation depending on the genetic material and the targeted tissue. To adapt the delivery system to the need, a wide variety of lipids that modulate the encapsulation efficiency and the LNP properties is needed for therapeutic success.
Join this webinar to hear how Polyplus developed LipidBrick® IM21.7c to overcome current limitations of ionizable lipids by enabling a wider in vivo biodistribution and decreasing accumulation in the liver. LipidBrick® IM21.7c aims to to improve LNP formulation to meet the growing demand of the mRNA therapeutic market.
